Related references
Note: Only part of the references are listed.
Letter
Hematology
Guillaume Roberge et al.
Summary: Vaccine-induced immune thrombotic thrombocytopenia (VITT) has been identified as a complication of adenovirus vector-based COVID-19 vaccines. It is associated with significant morbidity and mortality due to thrombosis-related complications. Diagnosis is confirmed through the detection of anti-PF4 antibodies using platelet factor 4 ELISA and platelet-activation assay. Although initial treatment strategy has been established, long-term management and follow-up remain uncertain.
THROMBOSIS RESEARCH
(2023)
Article
Chemistry, Medicinal
Liyan Yang et al.
Summary: The ongoing COVID-19 pandemic has highlighted the urgent need for potent prophylactic and therapeutic strategies against SARS-CoV-2. Small molecule inhibitors play a crucial role in the clinical treatment of SARS-CoV-2. China has made significant progress in the development of anti-SARS-CoV-2 drugs, but there is still limited knowledge regarding their pharmacological activity, antiviral mechanisms, and clinical efficacy. This review discusses the development of small molecule anti-SARS-CoV-2 drugs in China and summarizes their pharmacological activity, potential mechanisms of action, clinical trials and use, and important milestones in their discovery.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
(2023)
Article
Hematology
Linda Schoenborn et al.
Summary: In an observational study on vaccine-induced thrombotic thrombocytopenia (VITT), it was found that the platelet-activating antibodies in most patients are transient, and it is safe for VITT patients to receive a second dose of COVID-19 mRNA vaccine.
Article
Medicine, General & Internal
Lulu Bravo et al.
Summary: The SCB-2019 vaccine, supplemented with CpG and alum, provides significant protection against COVID-19 caused by different SAR-CoV-2 viruses, including the dominant Delta variant.
Article
Hematology
Brian Craven et al.
Summary: The COVID-19 pandemic has led to the rapid development of vaccines against SARS-CoV-2. Vaccine-induced immune thrombocytopenia and thrombosis (VITT) is a rare but life-threatening complication. This study measured the levels of antibodies, platelets, and D-dimer in a large cohort of patients and examined their relation to relapse. The results showed that most patients remained positive after diagnosis, but the relapse rate was low and did not result in a recurrence of severe clinical symptoms.
Article
Medicine, General & Internal
A. M. Price et al.
Summary: In this study evaluating BNT162b2, vaccine effectiveness against hospitalization for Covid-19 in the delta-predominant period among adolescents 12 to 18 years of age was more than 90%; during the omicron period, vaccine effectiveness was 40% against hospitalization and 79% against critical illness. Vaccine effectiveness against hospitalization was 68% among children 5 to 11 years of age.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Letter
Medicine, General & Internal
Elena Azzolini et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2022)
Article
Clinical Neurology
Quan-Ting Chen et al.
Summary: This study reports a case of vaccine-induced thrombotic thrombocytopenia in a patient who received two doses of AstraZeneca vaccine followed by a booster of Moderna vaccine, resulting in acute cerebral venous thrombosis and hemorrhage. Laboratory findings included thrombocytopenia, elevated D-dimer, and anemia.
FRONTIERS IN NEUROLOGY
(2022)
Review
Plant Sciences
Zhonglei Wang et al.
Summary: Traditional Chinese herbal medicines have shown promising potential for treating COVID-19, including active ingredients, monomer preparations, crude extracts, and formulas, all of which have potential activity against SARS-CoV-2 and have shown significant effects both in vitro and in clinical practice. As a key component of the COVID-19 treatment regimen, Chinese herbal medicines have played an irreplaceable role in the treatment of SARS-CoV-2 infection.
JOURNAL OF ETHNOPHARMACOLOGY
(2021)
Article
Virology
Gabriele Anichini et al.
Summary: The study found that patients with severe COVID-19 infection had significantly higher neutralizing antibody responses compared to those with mild symptoms, indicating potential implications for immunity strategy and vaccine development. The research also observed a declining trend in humoral immunity among pauci-symptomatic individuals, highlighting the need for further understanding of long-term immunity against SARS-CoV-2.
JOURNAL OF MEDICAL VIROLOGY
(2021)
Article
Public, Environmental & Occupational Health
et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
(2021)
Article
Medicine, General & Internal
Ronen Arbel et al.
Summary: Among 843,208 participants in Israel aged 50 years or older who had received two doses of the BNT162b2 vaccine at least 5 months earlier, those who received a booster had 90% lower mortality due to Covid-19 than those who did not receive a booster during the 54-day study period.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
Merryn Voysey et al.
Summary: The AZD1222 vaccine has been approved for emergency use in the UK with an interval of 4-12 weeks between doses. Analysis shows that the vaccine is efficacious with two doses and provides immunoprotection after the first dose before the second dose is administered.
Letter
Hematology
Carmen Rodriguez et al.
THROMBOSIS RESEARCH
(2021)
Article
Immunology
Dennis McGonagle et al.
Summary: The study explores the involvement of venous immunothrombotic mechanisms in SARS-CoV-2 infection and anti-SARS-CoV-2 DNA vaccination. It suggests that both SARS-CoV-2 infection and DNA vaccines may activate immune responses leading to autoimmunity and thrombosis, particularly in the venous system.
JOURNAL OF AUTOIMMUNITY
(2021)
Article
Immunology
Albrecht Guenther et al.
Summary: This study reported a VITT patient with an extremely severe condition, showing high titers of PF4-IgG antibodies, and described the treatment process and outcomes. Plasma exchange, immunoadsorption, and/or immunosuppressive treatment may be considered in such cases to reduce the high levels of anti-PF4-IgG.
Article
Medicine, General & Internal
Marie Scully et al.
Summary: 23 cases of thrombotic thrombocytopenia were reported after receiving the AstraZeneca vaccine, incited by antibodies to platelet factor 4 and unrelated to heparin therapy. Avoidance of platelet transfusion and consideration of nonheparin anticoagulant and intravenous immune globulin are recommended for treatment.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Letter
Medicine, General & Internal
Kate-Lynn Muir et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
Nina H. Schultz et al.
Summary: This study reports five cases of venous thrombosis and thrombocytopenia occurring 7 to 10 days after receiving the ChAdOx1 nCoV-19 vaccine, suggesting a rare vaccine-induced immune thrombotic thrombocytopenia. The condition, which can lead to catastrophic outcomes such as cerebral venous sinus thrombosis, may be treated with intravenous immune globulin.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
Andreas Greinacher et al.
Summary: After vaccination with ChAdOx1 nCov-19, rare immune thrombotic thrombocytopenia can occur due to platelet-activating antibodies against PF4, resulting in various thrombotic events. Most patients in this case series were women, with fatal outcomes such as cerebral venous thrombosis and intracranial hemorrhage. Additional studies are needed to further investigate and understand this phenomenon.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Hematology
Guenalp Uzun et al.
Article
Medicine, General & Internal
Robert W. Frenck et al.
Summary: The BNT162b2 vaccine showed favorable safety profile and a greater immune response in 12-to-15-year-old recipients compared to young adults, and demonstrated high effectiveness against Covid-19.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
Sue Pavord et al.
Summary: Phenotypes of VITT were defined in 220 patients in the United Kingdom who presented a median of 14 days after the first ChAdOx1 nCoV-19 vaccination. Half had cerebral venous sinus thrombosis, a third of whom also had intracranial hemorrhage. Mortality was 22%. Intravenous immune globulin may reverse VITT.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Letter
Medicine, General & Internal
Christopher J. Patriquin et al.
Summary: Therapeutic plasma exchange was effective in treating refractory VITT in three patients, who showed poor response to initial therapy with anticoagulants and intravenous immune globulin. Their conditions improved and they were discharged from the hospital after the treatment.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Letter
Medicine, General & Internal
Linda Schoenborn et al.
Summary: The study found that pathogenic antibodies in VITT patients decreased after receiving adenoviral vector Covid-19 vaccines, with improvements in platelet activation despite persistent positivity on ELISA. Additionally, 5 patients received additional vaccination without any sequelae.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Biochemistry & Molecular Biology
Brian Hetrick et al.
Summary: The study found that the traditional medicine oral liquid "Respiratory Detox Shot" (RDS) has potential anti-coronavirus activity, inhibiting the infection of various coronaviruses and influenza viruses.
CELL AND BIOSCIENCE
(2021)
Article
Biochemistry & Molecular Biology
P Chen et al.
